Trial Profile

A Prospective, Open-label Explorative Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Pyrotinib (Primary) ; Trastuzumab rezetecan (Primary)
Indications Advanced breast cancer
Focus Therapeutic Use

Most Recent Events

09 Oct 2024 Planned number of patients changed from 100 to 125.
04 Jun 2024 Interim results( Between March 31, 2023, and November 3, 2023, n=25 ) evaluating the use of a novel HER2-target ADC SHR-A1811 in HER2-expressing BCBM, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
17 Oct 2023 Planned number of patients changed from 75 to 100.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com